Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 6Unknown 2Recruiting 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Colorectal Neoplasms 6Neoplasm Metastasis 4Colonic Neoplasms 4Rectal Neoplasms 3Stomach Neoplasms 2Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Disease Progression 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 34pembrolizumab 26Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Folfox protocol × Clear all
NCT04729205 2023-09-14

Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies

Lipomedix Pharmaceuticals Inc.

Phase 1 Terminated
9 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡